Rockefeller Generic Rx Bill Would Penalize Brands For Failed Patent Defense
Executive Summary
Generic drug legislation floated by Sen. Jay Rockefeller (D-W.Va.) would create a drug reimbursement fund to compensate parties denied access to generic drugs due to litigation
You may also be interested in...
FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation
FTC Backs Single 30-Month Stay On Generic Rx Approvals In Patent Litigation
The Federal Trade Commission supports a limit of one 30-month stay of approval on generic drugs in patent litigation
“Orange Book” Certifications Would List Patent Claims Under Rockefeller Bill
"Orange Book" patent certifications would include an enumeration of the relevant claims under generic drug reform legislation introduced by Sen. Jay Rockefeller (D-W.Va.)